Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma

Mohit Kasibhatla, Peter Steinberg, Jeffrey Meyer, Marc S. Ernstoff, Daniel J. George

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Sorafenib, an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor and Raf/mitogen-activated protein kinase, increases progression-free survival in metastatic renal cell carcinoma (RCC) compared with placebo. The efficacy and toxicity of combined sorafenib and radiation therapy (RT) in the treatment of RCC are unknown. This is a retrospective report of 3 consecutive patients with metastatic or locally recurrent RCC treated with palliative RT while undergoing sorafenib therapy. All 3 patients experienced disease progression on sorafenib and remained on the drug without dose reduction during the RT plus sorafenib regimen. They were followed for toxicity and response by clinical history, physical examination, and contrast-enhanced computed tomography scans. Soon after completion of palliative RT, all 3 patients experienced complete pain relief without the need for narcotic pain medication. Posttreatment imaging revealed partial response with > 50% regression of tumor in all patients. None reported significant acute or late side effects at follow-up of 3, 6, and 8 months after RT and sorafenib. In the 3 patients with recurrent or metastatic RCC in this report, the combination of RT and sorafenib was well tolerated and resulted in excellent clinical and radiologic responses. This combination is promising and requires further study.

Original languageEnglish (US)
Pages (from-to)291-294
Number of pages4
JournalClinical Genitourinary Cancer
Issue number4
StatePublished - Mar 2007
Externally publishedYes


  • Palliative therapy
  • Progressive disease
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this